The use of cardiomyocyte-specific MT and Nrf2 transgenics that were shown to alleviate DM-induced cardiac fibrosis will allow us to determine whether lung fibrosis occurs independently from cardiac fibrosis, should these mice still develop lung fibrosis. This evidence concerns the gene NFE2L2 and pulmonary fibrosis.